GI Dynamics (ASX:GID) CEO Scott Schorer has had an uphill battle over the past year. His company has faced regulatory and compliance issues, negative shareholder sentiment and a number of other concerns.
But Schorer and his team are committed to righting the ship and saving a product they see as having no equal in the current marketplace – even if that turnaround requires difficult decisions be made.
“The main guiding light at GI Dynamics is that the EndoBarrier is a phenomenal product,” Schorer told MassDevice.com in an interview. “We are firmly committed to making sure that this technology survives for the patients and the shareholders. It’s worth saving.”
The EndoBarrier device is a plastic gut sleeve designed to prevent the absorption of nutrients from food as it exits the stomach and enters the intestinal tract to treat Type II diabetes and obesity.